LONDON, December 22, 2025 (ITIA Media Release)

The International Tennis Integrity Agency (ITIA) today confirms that Jessica Eudovic, an 18-year-old tennis player from the United States of America, has been provisionally suspended under the Tennis Anti-Doping Programme (TADP).

The ITIA sent the player a pre-charge notice of an Anti-Doping Rule Violation on 21 November 2025 under Article 2.1 of the TADP (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid Therapeutic Use Exemption (TUE)).

Eudovic, who reached a career-high ITF singles ranking of 1104 in October 2025, provided an in-competition sample while competing in an ITF World Tennis Tour W15 event in Santa Tecla, El Salvador, on 1 October 2025.

The sample was split into A and B samples and the subsequent analysis found that both samples contained a metabolite of clostebol, which is prohibited under the TADP, in the category of Anabolic Androgenic Steroids (section S1.1 of the 2025 World Anti-Doping Agency Prohibited List).

Clostebol is a non-Specified substance, and Eudovic did not possess a valid TUE for the substance.

Findings for non-Specified Substances carry a mandatory provisional suspension – in Eudovic’s case, this has been in effect from 21 November 2025.

Players have the right to appeal the imposition of their provisional suspension before an independent tribunal chair. On 1 December 2025, Eudovic filed an appeal, which was dismissed on 16 December 2025 by independent chair Dr Tanja Haug, who stated that the basis of Eudovic’s appeal was “insufficient to meet the threshold required to lift a Provisional Suspension.”

While provisionally suspended, Eudovic is prohibited from playing in, coaching at, or attending any tennis event authorised or sanctioned by the members of the ITIA (ATP, ITF, WTA, Tennis Australia, Fédération Française de Tennis, Wimbledon and USTA) or any national association.